14th Adriatic Congress of Pharmacoeconomics and Outcomes Research with focus on CEE

April 23-25, 2026, Brijuni, Croatia

Dear Colleague,

It is our great pleasure to invite you to participate in the 14th Adriatic Congress of Pharmacoeconomics and Outcomes Research with focus on CEE, which will be held at the Conference Centre of hotel Istra, Brijuni, Croatia, on April 23-25, 2026, and will be organized by the Section for Pharmacoeconomics and Outcomes Research of the Croatian Society of Clinical Pharmacology and Therapeutics, Croatian Medical Association.

The main objective of this year congress is to intensify and enhance professional and scientific discussions and collaboration between various stakeholders in support of the following overarching topic:

During the same time, the capacity of CEE countries has strengthened across academia, government institutions, and the health technology industry. Importantly, patient organizations have also evolved into increasingly effective partners within this ecosystem. These developments suggest that the necessary preconditions are now in place to move beyond problem identification and toward the implementation of optimal, collaborative solutions. Achieving this will require active engagement from all relevant stakeholders, working together to define, agree upon, and implement these solutions. The Congress therefore invites contributions that advance scholarly debate and evidence‑based policy dialogue across the following thematic domains:

•    Sustainable models for ensuring equitable patient access to, and long‑term financing of, medical innovation in Central and Eastern Europe (CEE)
•    Strengthening the role of patients and patient‑reported perspectives in healthcare decision‑making and policy development across CEE countries
•    Critical reflections and lessons learned from the implementation of the European Union Health Technology Assessment (EU HTA) Regulation
•    Strategic and systemic implications of the new European Pharmaceutical Strategy for national healthcare systems and innovation uptake
•    Health‑economic evaluations and outcomes research in selected therapeutic areas of particular relevance to CEE healthcare priorities
•    The integration of patient‑centred outcomes as key performance indicators informing national healthcare strategies, planning, and policy evaluation

Additionally, the full congress agenda will also comprise other important topics as well, such as development of healthcare policies, pharmaceutical pricing and reimbursement, comparative efficacy studies, outcomes research, value of health and health interventions, and many others.

Based on previous experience and recognized regional importance of this congress, we are expecting around 120-160 participants, attending in person, from more than 12 countries of Central, South and East Europe, from different fields, personally contributing and working together for the success of this congress and positive impact it has on fostering collaboration at national and regional levels.

We encourage your participation by submitting research podium and poster papers. As every year, we will organize several plenary sessions, round table discussion, issue panels, and research presentations.

It is important to note that we, as the organizers, will ensure participation of a wide range of stakeholders within the health care: the healthcare professionals (local, regional and international), members of academia, different associations, regulatory and payer authorities, politicians, and last but not least the pharmaceutical industry.

The overarching goal of the Congress is to advance public health care policies in order to maximize societal welfare and optimize diffusion of and access to innovative health care technologies, so that patients can reach their full life and health potential.

We are cordially looking forward to seeing you soon at the beautiful Brijuni island, Croatia!
With kindest regards, and on behalf of Congress Organizing Committee,

Prof. Dinko VITEZIĆ, MD, PhD Congress Chair
President, Section for Pharmacoeconomics and Outcomes Research,                                                                                                                                                                   Croatian Society for Clinical Pharmacology and Therapeutics